PMC:7253235 / 41297-42100 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T7","span":{"begin":644,"end":647},"obj":"https://glytoucan.org/Structures/Glycans/G00063MO"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1378","span":{"begin":445,"end":453},"obj":"Species"},{"id":"1394","span":{"begin":0,"end":14},"obj":"Disease"},{"id":"1395","span":{"begin":34,"end":40},"obj":"Disease"},{"id":"1396","span":{"begin":59,"end":73},"obj":"Disease"},{"id":"1397","span":{"begin":75,"end":86},"obj":"Disease"},{"id":"1398","span":{"begin":92,"end":100},"obj":"Disease"},{"id":"1399","span":{"begin":128,"end":134},"obj":"Disease"},{"id":"1400","span":{"begin":188,"end":196},"obj":"Disease"},{"id":"1401","span":{"begin":210,"end":228},"obj":"Disease"},{"id":"1402","span":{"begin":253,"end":262},"obj":"Disease"},{"id":"1403","span":{"begin":504,"end":507},"obj":"Disease"},{"id":"1404","span":{"begin":562,"end":574},"obj":"Disease"},{"id":"1405","span":{"begin":649,"end":660},"obj":"Disease"},{"id":"1406","span":{"begin":665,"end":668},"obj":"Disease"}],"attributes":[{"id":"A1378","pred":"tao:has_database_id","subj":"1378","obj":"Tax:9606"},{"id":"A1394","pred":"tao:has_database_id","subj":"1394","obj":"MESH:D066126"},{"id":"A1395","pred":"tao:has_database_id","subj":"1395","obj":"MESH:D009369"},{"id":"A1396","pred":"tao:has_database_id","subj":"1396","obj":"MESH:D009202"},{"id":"A1397","pred":"tao:has_database_id","subj":"1397","obj":"MESH:D001145"},{"id":"A1398","pred":"tao:has_database_id","subj":"1398","obj":"MESH:D007511"},{"id":"A1399","pred":"tao:has_database_id","subj":"1399","obj":"MESH:D009369"},{"id":"A1400","pred":"tao:has_database_id","subj":"1400","obj":"MESH:C000657245"},{"id":"A1401","pred":"tao:has_database_id","subj":"1401","obj":"MESH:D006338"},{"id":"A1402","pred":"tao:has_database_id","subj":"1402","obj":"MESH:D003643"},{"id":"A1403","pred":"tao:has_database_id","subj":"1403","obj":"MESH:D002318"},{"id":"A1404","pred":"tao:has_database_id","subj":"1404","obj":"MESH:D050171"},{"id":"A1405","pred":"tao:has_database_id","subj":"1405","obj":"MESH:D001145"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T409","span":{"begin":34,"end":40},"obj":"Disease"},{"id":"T410","span":{"begin":59,"end":73},"obj":"Disease"},{"id":"T411","span":{"begin":75,"end":86},"obj":"Disease"},{"id":"T412","span":{"begin":128,"end":134},"obj":"Disease"},{"id":"T413","span":{"begin":188,"end":196},"obj":"Disease"},{"id":"T414","span":{"begin":222,"end":228},"obj":"Disease"},{"id":"T415","span":{"begin":551,"end":554},"obj":"Disease"},{"id":"T416","span":{"begin":562,"end":574},"obj":"Disease"},{"id":"T417","span":{"begin":644,"end":647},"obj":"Disease"},{"id":"T419","span":{"begin":649,"end":660},"obj":"Disease"},{"id":"T420","span":{"begin":665,"end":668},"obj":"Disease"},{"id":"T421","span":{"begin":792,"end":803},"obj":"Disease"}],"attributes":[{"id":"A409","pred":"mondo_id","subj":"T409","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A410","pred":"mondo_id","subj":"T410","obj":"http://purl.obolibrary.org/obo/MONDO_0004994"},{"id":"A411","pred":"mondo_id","subj":"T411","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"},{"id":"A412","pred":"mondo_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A413","pred":"mondo_id","subj":"T413","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A414","pred":"mondo_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A415","pred":"mondo_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A416","pred":"mondo_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/MONDO_0002525"},{"id":"A417","pred":"mondo_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A418","pred":"mondo_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/MONDO_0018922"},{"id":"A419","pred":"mondo_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"},{"id":"A420","pred":"mondo_id","subj":"T420","obj":"http://purl.obolibrary.org/obo/MONDO_0005009"},{"id":"A421","pred":"mondo_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T309","span":{"begin":285,"end":292},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T116","span":{"begin":336,"end":344},"obj":"Chemical"}],"attributes":[{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T28","span":{"begin":740,"end":746},"obj":"http://purl.obolibrary.org/obo/GO_0048511"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T225","span":{"begin":34,"end":40},"obj":"Phenotype"},{"id":"T226","span":{"begin":59,"end":73},"obj":"Phenotype"},{"id":"T227","span":{"begin":75,"end":86},"obj":"Phenotype"},{"id":"T228","span":{"begin":128,"end":134},"obj":"Phenotype"},{"id":"T229","span":{"begin":157,"end":165},"obj":"Phenotype"},{"id":"T230","span":{"begin":222,"end":228},"obj":"Phenotype"},{"id":"T231","span":{"begin":562,"end":574},"obj":"Phenotype"},{"id":"T232","span":{"begin":649,"end":660},"obj":"Phenotype"},{"id":"T233","span":{"begin":665,"end":668},"obj":"Phenotype"},{"id":"T234","span":{"begin":792,"end":803},"obj":"Phenotype"}],"attributes":[{"id":"A225","pred":"hp_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A226","pred":"hp_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/HP_0001638"},{"id":"A227","pred":"hp_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/HP_0011675"},{"id":"A228","pred":"hp_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A229","pred":"hp_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A230","pred":"hp_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A231","pred":"hp_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/HP_0003119"},{"id":"A232","pred":"hp_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/HP_0011675"},{"id":"A233","pred":"hp_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A234","pred":"hp_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/HP_0011675"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}

{"project":"LitCovid-sentences","denotations":[{"id":"T262","span":{"begin":0,"end":262},"obj":"Sentence"},{"id":"T263","span":{"begin":263,"end":425},"obj":"Sentence"},{"id":"T264","span":{"begin":426,"end":575},"obj":"Sentence"},{"id":"T265","span":{"begin":576,"end":721},"obj":"Sentence"},{"id":"T266","span":{"begin":722,"end":803},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality\n• Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms\n• Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)\n• Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary\n• Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias"}